🇺🇸 FDA
Pipeline program

Ketamine

2853-15-SMC

Approved small_molecule active

Quick answer

Ketamine for Treatment Resistant Depression is a Approved program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Treatment Resistant Depression
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials